ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
Tag: Ficlatuzumab
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
Authors: Tony Shu Kam Mok, Sarayut Lucien Geater, Wu-Chou Su, Eng-Huat Tan, James Chi-Hsin Yang, Gee-Chen Chang, May Han, Philip Komarnitsky, Francis Payumo, Jennifer E. Garrus, Sandra Close, Keunchil Park. Click here for link to article.
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors